(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:
----------
Gresham House Strategic PLC - investor in smaller UK public companies - Launches strategic review as David Potter plans to retire as chair at the September annual general meeting and company receives request from major shareholder Gresham House PLC for an extraordinary general meeting to remove Potter. The London-based asset manager wants Potter to be removed from the board immediately and Jeston Na Nakhorn to be appointed to the board of Gresham House Strategic as a representative of Gresham House. It wants Helen Sinclair, a current non-executive director of GHS, to become interim chair until the AGM and Kenneth Lever, another non-executive director, to become senior independent director. Gresham House also wants a strategic review of GHS by July 12. This would determine the "best means of maximising value for shareholders including consideration of a realisation of the invested assets of GHS". Gresham House Strategic says that, in view of its own announcement of a strategic review and the retirement of Potter, it will consult with Gresham House about its proposed meeting resolutions. It says its strategic review will include considering Gresham House Asset Management's continued role as asset manager, and therefore it has served 12 months notice to GHAM.
----------
City of London Group PLC - owns UK small-business lender Recognise Bank - Colin Wagman will retire as non-executive chair on June 10, replaced by Philip Jenks, an independent non-executive director of COLG and chair of subsidiary Recognise Bank.
----------
Nuformix PLC - Cambridge, England-based pharmaceutical firm focused fibrosis and oncology - Hires Alastair Riddell as non-executive chair, effective immediately. Riddell is a medical doctor who was chair of AIM-listed Feedback PLC and also served as CEO of three UK biotech firms. Meanwhile, Karl Keegan resigns as non-executive director, effective immediately, and Joanne Holland as chief scientific officer, from the end of May. Holland will remain a consultant to Nuformix.
----------
ImmuPharma PLC - London-based developer of peptide-based therapeutics - Robert Zimmer will retire as chief science officer and from the board at the annual general meeting on June 28. Zimmer is a large shareholder in ImmuPharma and has agreed to not sell shares for three years or, if earlier, the date the company reports the preliminary results of the next Phase 3 clinical trial of its lead drug candidate Lupuzor.
----------
Iconic Labs PLC - London-based media and technology company - Hires Marija Hrebac as non-executive director, starting immediately. Hrebac is CEO of the Deposit Insurance & Bank Resolution Agency in Croatia.
----------
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Immupharma (IMM)
Nuformix (NFX)
Feedback (FDBK)
Iconic Labs (ICON)